Description
Anti-58P1D12 Antibody, Non-Fucosylated (BioBet-489ZP) is a human monoclonal IgG antibody against 58P1D12. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced 58P1D12 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
58P1D12 antibody are particularly useful in cancer diagnostic and prognostic assays, and imaging methodologies. Similarly, such antibody are useful in the treatment, diagnosis, and/or prognosis of ovarian and other cancers, to the extent 58P1D12 is also expressed or overexpressed in these other cancers.
Antibody Indication
Cancer
